As MaR2 and MaR1 each modulate conjunctival goblet cell function, they each may have potential as novel, but differing, options for treatment of ocular surface inflammatory diseases including allergic conjunctivitis and dry eye disease. Here, PEG10 is linked to atopic conjunctivitis.